Other languages AstraZeneca PLC Nasdaq Stockholm

Equities

AZN

GB0009895292

Real-time Estimate Cboe Europe Other stock markets 06:51:51 27/06/2024 pm IST			5-day change	1st Jan Change
1,674 ^SEK	-0.03%		+1.86%	+23.72%

12:39pm	US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	RE
26/06	European Equities Close Lower in Wednesday Trading	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ETF der Woche: Europäische Anlage abseits Frankreichs	06:07pm
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	04:09pm
European Equities Close Lower in Wednesday Trading	26/06
ETF de la semaine : Investir en Europe hors France pour contourner le risque politique	26/06
AstraZeneca Says Tagrisso With Chemotherapy Approved in China	26/06
AstraZeneca : Tagrisso approuvé en Chine dans le CPNPC	26/06
AstraZeneca's Tagrisso plus chemo gets approval in China	26/06
China approves AstraZeneca's Tagrisso-chemo combo as first-line treatment	26/06
AstraZeneca Wins Chinese Regulatory Nod for Lung Cancer Combination Treatment	26/06
Airbus belastet DAX - OMX profitiert vom Abnehmhype	25/06
European Equities Close Lower in Tuesday Trading; EC Accuses Microsoft of Breaking Antitrust Laws	25/06
European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading	25/06
Airbus belastet den DAX - OMX profitiert vom Abnehmhype	25/06
AstraZeneca Says Imfinzi With Chemotherapy Improves Survival in Phase 3 Bladder Cancer Trial	25/06
AstraZeneca's Tagrisso Approved With Chemotherapy in Japan for Lung Cancer Treatment	25/06
AstraZeneca Says Phase 3 Imfinzi Trial in Early-Stage Lung Cancer Misses Primary Endpoint	25/06
AstraZeneca Logs Hit and Miss in Oncology Drugs Portfolio	25/06
MIDDAY BRIEFING - Unternehmen und Märkte -2-	25/06
AstraZeneca PLC Announces IMFINZI Demonstrates Statically Significant and Clinically Meaningful Improvement in Event-Free Survival and Overall Survival for Muscle-Invasive Bladder Cancer in Niagara Phase III Trial	25/06
AstraZeneca's Imfinzi fails in late-stage trial to treat certain lung cancers	25/06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 09:32 pm IST